Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
161-180 of 1,782 trials

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Eptinezumab for Pediatric Migraine Prevention

We are studying whether eptinezumab can help reduce the number of migraine days in children and teenagers with episodic migraines. This trial aims to find out if it is a safe and effective option for young patients.

MigraineConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ovarian Cancer: NiraParib Maintenance Study

We are studying whether three cycles of chemotherapy followed by the drug niraparib is as effective as six cycles for patients with advanced ovarian cancer. This trial focuses on those who have had their tumors completely removed and are HRD-positive.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Osteoporosis: Zoledronate After Denosumab

We are studying if zoledronate can prevent bone loss in patients with osteoporosis who have stopped denosumab treatment. This trial also looks at how this treatment affects muscle strength and insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngology

Relapsing Multiple Sclerosis: Rituximab vs. Ocrelizumab

We are studying whether rituximab is as effective as ocrelizumab for treating relapsing MS. This trial is for patients who are starting anti-CD20 therapy.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Relapsed/Refractory AML: Venetoclax and Decitabine Therapy

We are studying a new combination treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to see if this therapy can help achieve remission and improve safety and recovery outcomes.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Vulvar Carcinoma: Chemoradiation vs. Neoadjuvant Chemotherapy

We are comparing two treatment approaches for locally advanced vulvar carcinoma to see which is more effective and safe. We also want to understand how these treatments impact quality of life and the influence of HPV status.

LAVC (Locally Advanced Vulvar Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Wilms Tumor: Metronomic Chemotherapy Study

We are evaluating a new chemotherapy regimen for children and teenagers with relapsed or refractory Wilms tumor. The study aims to assess safety, effectiveness, and quality of life during treatment.

Wilms Tumor6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Ovarian Cancer: New Chemotherapy Approach

We are investigating a combined chemotherapy treatment for patients with advanced ovarian cancer after surgery. The study aims to assess its safety, effectiveness, and impact on quality of life.

Ovarian Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visitsStandard MedicinesDermatologyPediatrics

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Early-Stage Breast Cancer: Long-Term Follow-Up Study

We are examining the long-term health of early-stage breast cancer patients from previous studies. This research will help us understand relapse rates and overall survival.

Early Stage Invasive Breast Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Preeclampsia Intervention 4: Metformin for Preterm Preeclampsia

We are studying whether daily metformin can help prolong pregnancy in women with preterm preeclampsia. We also want to see if it improves outcomes for newborns, like increasing birth weight and reducing time in neonatal care.

Preeclampsia>2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsInternal Medicine

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Head and Neck Cancer: New Imaging Technique

We are testing a new near-infrared imaging method to help surgeons detect remaining cancer cells during surgery. This study aims to improve the accuracy of tumor removal and preserve healthy tissue.

Head and Neck Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

Rituximab for Amyotrophic Lateral Sclerosis (ALS)

We are studying whether adding Rituximab to standard treatment can slow symptom progression in ALS patients. The trial also monitors safety and various health indicators.

Sporadic Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Laryngeal Cancer: ELOS Study on New Treatment

We are studying whether adding pembrolizumab to standard chemotherapy and radiation helps patients with advanced laryngeal cancer avoid laryngectomy. This trial also examines the impact on swallowing quality and overall survival.

Advanced Laryngeal and Hypopharyngeal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology